Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Cyclin-dependent kinase inhibitor 2A (Cyclin-dependent kinase 4 inhibitor A) (CDK4I) (p16-INK4a) (p16-INK4)

 CDN2A_MOUSE             Reviewed;         168 AA.
P51480; A2ANM1; A2ANM2; O89088; P97510; P97937; Q6PEA2; Q78E39;
Q78E57; Q792X7; Q9QWH6; Q9QWH7; Q9QWH8;
01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
25-OCT-2005, sequence version 2.
05-JUL-2017, entry version 154.
RecName: Full=Cyclin-dependent kinase inhibitor 2A {ECO:0000312|MGI:MGI:104738};
AltName: Full=Cyclin-dependent kinase 4 inhibitor A;
Short=CDK4I;
AltName: Full=p16-INK4a;
Short=p16-INK4;
Name=Cdkn2a {ECO:0000312|MGI:MGI:104738}; Synonyms=P16ink4a;
Mus musculus (Mouse).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha;
Muroidea; Muridae; Murinae; Mus; Mus.
NCBI_TaxID=10090;
[1]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
PubMed=7651726;
Quelle D.E., Ashmun R.A., Hannon G.J., Rehberger P.A., Trono D.,
Richter K.H., Walker C., Beach D., Sherr C.J., Serrano M.;
"Cloning and characterization of murine p16INK4a and p15INK4b genes.";
Oncogene 11:635-645(1995).
[2]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS PRO-18; ILE-51;
MET-74; TYR-75 AND ARG-90.
STRAIN=BALB/cJ, and DBA/2N; TISSUE=Spleen;
PubMed=9482902; DOI=10.1073/pnas.95.5.2429;
Zhang S., Ramsay E.S., Mock B.A.;
"Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16(INK4a) and
p19(ARF), is a candidate for the plasmacytoma susceptibility locus,
Pctr1.";
Proc. Natl. Acad. Sci. U.S.A. 95:2429-2434(1998).
[3]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
STRAIN=129/SvJ;
Gong Z., Li J., Fu J.;
"Cloning and structure analysis of murine p16INK4a.";
Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
[4]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
PubMed=16141072; DOI=10.1126/science.1112014;
Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
Hayashizaki Y.;
"The transcriptional landscape of the mammalian genome.";
Science 309:1559-1563(2005).
[5]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
STRAIN=C57BL/6J;
PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
Lindblad-Toh K., Eichler E.E., Ponting C.P.;
"Lineage-specific biology revealed by a finished genome assembly of
the mouse.";
PLoS Biol. 7:E1000112-E1000112(2009).
[6]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-155.
STRAIN=C57BL/6J X DBA;
PubMed=9178896; DOI=10.1038/sj.onc.1200969;
Malumbres M., de Castro I.P., Santos J., Melendez B., Mangues R.,
Serrano M., Pellicer A., Fernandez-Piqueras J.;
"Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by
deletion and de novo methylation with independence of p16INK4a
alterations in murine primary T-cell lymphomas.";
Oncogene 14:1361-1370(1997).
[7]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-155, AND VARIANTS PRO-18;
ILE-51; GLN-90 AND SER-127.
STRAIN=BALB/cJ, C57BL/6J, CAST/EiJ, MOLF/EiJ, and RF/J;
Santos J., Melendez B., Perez de Castro I., Malumbres M., Serrano M.,
Pellicer A., Fernandez-Piqueras J.;
"Comparative analysis of the p16(INK4a) and p15(INK4b) DNA sequences
in mouse inbred strains.";
Submitted (OCT-1996) to the EMBL/GenBank/DDBJ databases.
[8]
NUCLEOTIDE SEQUENCE [MRNA] OF 1-42 (ISOFORM 1), AND VARIANT PRO-18.
STRAIN=020, 129/J, A/J, A/Wy, AKR/J, B10.A, B10.D2(58N), BALB/cJ,
C3H/21BG, C3H/HeJ, C57BL/10ScNJ, C57BL/10SN, C57BL/6By, C57BL/6J,
C57BR/cdJ, CBA/J, DBA/2J, HS/IBG, LP/J, LS/IBG, MA/M4J, PL/J, RF/J,
Sencar, SJL/J, SM/J, ST/J, and SWR/J; TISSUE=Lung;
PubMed=9021155; DOI=10.1007/s003359900352;
Herzog C.R., You M.;
"Sequence variation and chromosomal mapping of the murine Cdkn2a tumor
suppressor gene.";
Mamm. Genome 8:65-66(1997).
[9]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-42, AND VARIANTS VAL-12; GLU-27
AND LEU-73.
PubMed=9667743; DOI=10.1093/carcin/19.6.1045;
Gressani K.M., Rollins L.A., Leone-Kabler S., Cline J.M., Miller M.S.;
"Induction of mutations in Ki-ras and INK4a in liver tumors of mice
exposed in utero to 3-methylcholanthrene.";
Carcinogenesis 19:1045-1052(1998).
[10]
MUTAGENESIS OF CYS-64; ASP-76 AND 84-ASP-THR-85.
PubMed=9012842; DOI=10.1073/pnas.94.2.669;
Quelle D.E., Cheng M., Ashmun R.A., Sherr C.J.;
"Cancer-associated mutations at the INK4a locus cancel cell cycle
arrest by p16INK4a but not by the alternative reading frame protein
p19ARF.";
Proc. Natl. Acad. Sci. U.S.A. 94:669-673(1997).
-!- FUNCTION: Acts as a negative regulator of the proliferation of
normal cells by interacting strongly with CDK4 and CDK6. This
inhibits their ability to interact with cyclins D and to
phosphorylate the retinoblastoma protein.
-!- SUBUNIT: Heterodimer with CDK4 or CDK6. Predominamt P16 complexes
contained CDK6. Interacts with CDK4 (both 'T-172'-phosphorylated
and non-phosphorylated forms); the interaction inhibits cyclin D-
CDK4 kinase activity. Interacts with ISCO2 (By similarity).
{ECO:0000250}.
-!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
{ECO:0000250}.
-!- ALTERNATIVE PRODUCTS:
Event=Alternative splicing; Named isoforms=4;
Comment=Isoform 1 and isoform tumor suppressor ARF arise due to
the use of two alternative first exons joined to a common exon 2
at the same acceptor site but in different reading frames,
resulting in two completely different isoforms.;
Name=1; Synonyms=p16INK4a;
IsoId=P51480-1; Sequence=Displayed;
Name=2;
IsoId=P51480-2; Sequence=VSP_015867;
Name=tumor suppressor ARF; Synonyms=p19ARF;
IsoId=Q64364-1; Sequence=External;
Name=smARF;
IsoId=Q64364-2; Sequence=External;
-!- PTM: Phosphorylation seems to increase interaction with CDK4.
{ECO:0000250}.
-!- POLYMORPHISM: Strain BALB/c displays a significantly reduced
ability to inhibit phosphorylation of the retinoblastoma protein.
-!- SIMILARITY: Belongs to the CDKN2 cyclin-dependent kinase inhibitor
family. {ECO:0000305}.
-!- CAUTION: The proteins described here are encoded by the gene
CDKN2A, but are completely unrelated in term of sequence and
function to tumor suppressor ARF (AC Q64364) which is encoded by
the same gene. {ECO:0000305}.
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; L76150; AAA85453.1; -; mRNA.
EMBL; AF044335; AAC08962.1; -; mRNA.
EMBL; AF044336; AAC08963.1; -; mRNA.
EMBL; AF332190; AAK83159.1; -; Genomic_DNA.
EMBL; AK155307; BAE33180.1; -; mRNA.
EMBL; AL831719; CAM16002.1; -; Genomic_DNA.
EMBL; AL831719; CAM16003.1; -; Genomic_DNA.
EMBL; U66087; AAB39600.1; -; Genomic_DNA.
EMBL; U66086; AAB39600.1; JOINED; Genomic_DNA.
EMBL; U79625; AAD00223.1; -; Genomic_DNA.
EMBL; U79626; AAD00224.1; -; Genomic_DNA.
EMBL; U79627; AAD00225.1; -; Genomic_DNA.
EMBL; U79628; AAD00226.1; -; Genomic_DNA.
EMBL; U79630; AAD00227.1; -; Genomic_DNA.
EMBL; U79631; AAD00228.1; -; Genomic_DNA.
EMBL; U79632; AAD00229.1; -; Genomic_DNA.
EMBL; U49279; AAC00051.1; -; Genomic_DNA.
EMBL; U49280; AAC00052.1; -; Genomic_DNA.
EMBL; AF004588; AAB61416.1; -; Genomic_DNA.
CCDS; CCDS38812.1; -. [P51480-1]
RefSeq; NP_001035744.1; NM_001040654.1. [P51480-1]
UniGene; Mm.4733; -.
PDB; 1LNN; Model; -; A=12-159.
PDBsum; 1LNN; -.
ProteinModelPortal; P51480; -.
SMR; P51480; -.
BioGrid; 198654; 33.
DIP; DIP-60251N; -.
iPTMnet; P51480; -.
PhosphoSitePlus; P51480; -.
PeptideAtlas; P51480; -.
PRIDE; P51480; -.
Ensembl; ENSMUST00000060501; ENSMUSP00000061847; ENSMUSG00000044303. [P51480-1]
GeneID; 12578; -.
KEGG; mmu:12578; -.
UCSC; uc008toh.1; mouse. [P51480-1]
CTD; 1029; -.
MGI; MGI:104738; Cdkn2a.
GeneTree; ENSGT00390000008249; -.
HOVERGEN; HBG050870; -.
KO; K06621; -.
OMA; APNRYGR; -.
TreeFam; TF352389; -.
Proteomes; UP000000589; Chromosome 4.
Bgee; ENSMUSG00000044303; -.
CleanEx; MM_CDKN2A; -.
ExpressionAtlas; P51480; baseline and differential.
Genevisible; P51480; MM.
GO; GO:0005737; C:cytoplasm; IDA:MGI.
GO; GO:0001652; C:granular component; IEA:Ensembl.
GO; GO:0005739; C:mitochondrion; ISO:MGI.
GO; GO:0005730; C:nucleolus; IDA:MGI.
GO; GO:0005654; C:nucleoplasm; IDA:MGI.
GO; GO:0005634; C:nucleus; ISO:MGI.
GO; GO:0043234; C:protein complex; ISO:MGI.
GO; GO:0035985; C:senescence-associated heterochromatin focus; ISO:MGI.
GO; GO:0004861; F:cyclin-dependent protein serine/threonine kinase inhibitor activity; IDA:MGI.
GO; GO:0097718; F:disordered domain specific binding; ISO:MGI.
GO; GO:0097371; F:MDM2/MDM4 family protein binding; ISO:MGI.
GO; GO:0051059; F:NF-kappaB binding; ISO:MGI.
GO; GO:0002039; F:p53 binding; ISO:MGI.
GO; GO:0019901; F:protein kinase binding; ISO:MGI.
GO; GO:0047485; F:protein N-terminus binding; IPI:MGI.
GO; GO:0003723; F:RNA binding; ISO:MGI.
GO; GO:0019789; F:SUMO transferase activity; ISO:MGI.
GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IDA:MGI.
GO; GO:0008134; F:transcription factor binding; ISO:MGI.
GO; GO:1990948; F:ubiquitin ligase inhibitor activity; ISO:MGI.
GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; ISO:MGI.
GO; GO:0007568; P:aging; IMP:MGI.
GO; GO:1990000; P:amyloid fibril formation; ISO:MGI.
GO; GO:0008637; P:apoptotic mitochondrial changes; ISO:MGI.
GO; GO:0007569; P:cell aging; IDA:MGI.
GO; GO:0007050; P:cell cycle arrest; IDA:MGI.
GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:MGI.
GO; GO:0090398; P:cellular senescence; IDA:MGI.
GO; GO:0008544; P:epidermis development; IMP:MGI.
GO; GO:0000082; P:G1/S transition of mitotic cell cycle; ISO:MGI.
GO; GO:0042593; P:glucose homeostasis; IMP:MGI.
GO; GO:0051882; P:mitochondrial depolarization; ISO:MGI.
GO; GO:0000422; P:mitophagy; ISO:MGI.
GO; GO:0030889; P:negative regulation of B cell proliferation; IEA:Ensembl.
GO; GO:0045786; P:negative regulation of cell cycle; IDA:MGI.
GO; GO:0030308; P:negative regulation of cell growth; ISO:MGI.
GO; GO:0008285; P:negative regulation of cell proliferation; ISO:MGI.
GO; GO:0001953; P:negative regulation of cell-matrix adhesion; ISO:MGI.
GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:MGI.
GO; GO:0033088; P:negative regulation of immature T cell proliferation in thymus; IEA:Ensembl.
GO; GO:0033600; P:negative regulation of mammary gland epithelial cell proliferation; IMP:MGI.
GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; ISO:MGI.
GO; GO:0042326; P:negative regulation of phosphorylation; ISO:MGI.
GO; GO:0032091; P:negative regulation of protein binding; IDA:MGI.
GO; GO:0006469; P:negative regulation of protein kinase activity; ISO:MGI.
GO; GO:2000435; P:negative regulation of protein neddylation; ISO:MGI.
GO; GO:2000059; P:negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:MGI.
GO; GO:1903051; P:negative regulation of proteolysis involved in cellular protein catabolic process; IDA:MGI.
GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISO:MGI.
GO; GO:1904667; P:negative regulation of ubiquitin protein ligase activity; ISO:MGI.
GO; GO:0043065; P:positive regulation of apoptotic process; ISO:MGI.
GO; GO:0060058; P:positive regulation of apoptotic process involved in mammary gland involution; IMP:MGI.
GO; GO:0071158; P:positive regulation of cell cycle arrest; ISO:MGI.
GO; GO:2000774; P:positive regulation of cellular senescence; ISO:MGI.
GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; ISO:MGI.
GO; GO:0010628; P:positive regulation of gene expression; ISO:MGI.
GO; GO:2000111; P:positive regulation of macrophage apoptotic process; IGI:BHF-UCL.
GO; GO:1900182; P:positive regulation of protein localization to nucleus; ISO:MGI.
GO; GO:0033235; P:positive regulation of protein sumoylation; ISO:MGI.
GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IEA:Ensembl.
GO; GO:1901798; P:positive regulation of signal transduction by p53 class mediator; ISO:MGI.
GO; GO:0034393; P:positive regulation of smooth muscle cell apoptotic process; IGI:BHF-UCL.
GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISO:MGI.
GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISO:MGI.
GO; GO:0031648; P:protein destabilization; ISO:MGI.
GO; GO:0070534; P:protein K63-linked ubiquitination; ISO:MGI.
GO; GO:0000209; P:protein polyubiquitination; ISO:MGI.
GO; GO:0050821; P:protein stabilization; ISO:MGI.
GO; GO:1902510; P:regulation of apoptotic DNA fragmentation; ISO:MGI.
GO; GO:0000079; P:regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:MGI.
GO; GO:0010389; P:regulation of G2/M transition of mitotic cell cycle; ISO:MGI.
GO; GO:0010468; P:regulation of gene expression; IMP:MGI.
GO; GO:0046822; P:regulation of nucleocytoplasmic transport; IGI:MGI.
GO; GO:0046825; P:regulation of protein export from nucleus; ISO:MGI.
GO; GO:1903214; P:regulation of protein targeting to mitochondrion; ISO:MGI.
GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:MGI.
GO; GO:0090399; P:replicative senescence; ISO:MGI.
GO; GO:0009303; P:rRNA transcription; IGI:MGI.
GO; GO:0035986; P:senescence-associated heterochromatin focus assembly; ISO:MGI.
GO; GO:0048103; P:somatic stem cell division; IEA:Ensembl.
GO; GO:0035019; P:somatic stem cell population maintenance; IGI:MGI.
CDD; cd00204; ANK; 1.
Gene3D; 1.25.40.20; -; 2.
InterPro; IPR002110; Ankyrin_rpt.
InterPro; IPR020683; Ankyrin_rpt-contain_dom.
Pfam; PF12796; Ank_2; 1.
SMART; SM00248; ANK; 4.
SUPFAM; SSF48403; SSF48403; 1.
PROSITE; PS50297; ANK_REP_REGION; 1.
1: Evidence at protein level;
3D-structure; Alternative splicing; ANK repeat; Cell cycle;
Complete proteome; Cytoplasm; Nucleus; Phosphoprotein; Polymorphism;
Reference proteome; Repeat; Tumor suppressor.
CHAIN 1 168 Cyclin-dependent kinase inhibitor 2A.
/FTId=PRO_0000144178.
REPEAT 3 32 ANK 1.
REPEAT 36 64 ANK 2.
REPEAT 69 98 ANK 3.
REPEAT 102 131 ANK 4.
MOD_RES 152 152 Phosphoserine.
{ECO:0000250|UniProtKB:P42771}.
MOD_RES 164 164 Phosphoserine.
{ECO:0000250|UniProtKB:P42771}.
VAR_SEQ 1 43 Missing (in isoform 2). {ECO:0000305}.
/FTId=VSP_015867.
VARIANT 12 12 A -> V (in some liver tumors).
{ECO:0000269|PubMed:9667743}.
VARIANT 18 18 H -> P (in strain: 020, BALB/c, BALB/cJ,
C3H/21BG, C3H/HeJ, CBA/J, MA/M4J and PL/
J). {ECO:0000269|PubMed:9021155,
ECO:0000269|PubMed:9482902,
ECO:0000269|Ref.7}.
VARIANT 27 27 G -> E (in some liver tumors).
{ECO:0000269|PubMed:9667743}.
VARIANT 51 51 V -> I (in strain: BALB/c and BALB/cJ).
{ECO:0000269|PubMed:9482902,
ECO:0000269|Ref.7}.
VARIANT 73 73 P -> L (in some liver tumors).
{ECO:0000269|PubMed:9667743}.
VARIANT 74 74 V -> M (in plasmacytoma cell lines).
{ECO:0000269|PubMed:9482902}.
VARIANT 75 75 H -> Y (in plasmacytoma cell lines).
{ECO:0000269|PubMed:9482902}.
VARIANT 90 90 H -> Q (in strain: BALB/cJ, C57BL/6J and
MOLF/Ei). {ECO:0000269|Ref.7}.
VARIANT 90 90 H -> R (in plasmacytoma cell lines).
{ECO:0000269|PubMed:9482902}.
VARIANT 127 127 C -> S (in strain: BALB/cJ, C57BL/6J and
MOLF/Ei). {ECO:0000269|Ref.7}.
MUTAGEN 64 64 C->G,R: No effect on activity.
{ECO:0000269|PubMed:9012842}.
MUTAGEN 76 76 D->N: Loss of activity.
{ECO:0000269|PubMed:9012842}.
MUTAGEN 84 85 Missing: Loss of activity.
{ECO:0000269|PubMed:9012842}.
CONFLICT 11 11 Missing (in Ref. 1; AAA85453).
{ECO:0000305}.
SEQUENCE 168 AA; 17941 MW; 9A6B0F24F34D5FEC CRC64;
MESAADRLAR AAAQGRVHDV RALLEAGVSP NAPNSFGRTP IQVMMMGNVH VAALLLNYGA
DSNCEDPTTF SRPVHDAARE GFLDTLVVLH GSGARLDVRD AWGRLPLDLA QERGHQDIVR
YLRSAGCSLC SAGWSLCTAG NVAQTDGHSF SSSTPRALEL RGQSQEQS


Related products :

Catalog number Product name Quantity
15-288-21185 Cyclin-dependent kinase inhibitor 2A. isoforms 1_2_3 - Cyclin-dependent kinase 4 inhibitor A; CDK4I; p16-INK4; p16-INK4a; Multiple tumor suppressor 1; MTS1 Polyclonal 0.1 mg
15-288-21185 Cyclin-dependent kinase inhibitor 2A. isoforms 1_2_3 - Cyclin-dependent kinase 4 inhibitor A; CDK4I; p16-INK4; p16-INK4a; Multiple tumor suppressor 1; MTS1 Polyclonal 0.05 mg
E0794r ELISA kit CDK4I,Cdkn2a,Cyclin-dependent kinase 4 inhibitor A,Cyclin-dependent kinase inhibitor 2A, isoform 1,p16,p16-INK4,P16ink4a,p16-INK4a,Rat,Rattus norvegicus 96T
E0794r ELISA CDK4I,Cdkn2a,Cyclin-dependent kinase 4 inhibitor A,Cyclin-dependent kinase inhibitor 2A, isoform 1,p16,p16-INK4,P16ink4a,p16-INK4a,Rat,Rattus norvegicus 96T
E0794m ELISA CDK4I,Cdkn2a,Cyclin-dependent kinase 4 inhibitor A,Cyclin-dependent kinase inhibitor 2A, isoforms 1_2,Mouse,Mus musculus,p16-INK4,P16ink4a,p16-INK4a 96T
U0794r CLIA CDK4I,Cdkn2a,Cyclin-dependent kinase 4 inhibitor A,Cyclin-dependent kinase inhibitor 2A, isoform 1,p16,p16-INK4,P16ink4a,p16-INK4a,Rat,Rattus norvegicus 96T
E0794m ELISA kit CDK4I,Cdkn2a,Cyclin-dependent kinase 4 inhibitor A,Cyclin-dependent kinase inhibitor 2A, isoforms 1_2,Mouse,Mus musculus,p16-INK4,P16ink4a,p16-INK4a 96T
U0794m CLIA CDK4I,Cdkn2a,Cyclin-dependent kinase 4 inhibitor A,Cyclin-dependent kinase inhibitor 2A, isoforms 1_2,Mouse,Mus musculus,p16-INK4,P16ink4a,p16-INK4a 96T
U0794h CLIA CDK4I,CDKN2,CDKN2A,Cyclin-dependent kinase 4 inhibitor A,Cyclin-dependent kinase inhibitor 2A, isoforms 1_2_3,Homo sapiens,Human,MTS1,MTS-1,Multiple tumor suppressor 1,p16-INK4,p16INK4A,p16-INK4a 96T
E0794h ELISA CDK4I,CDKN2,CDKN2A,Cyclin-dependent kinase 4 inhibitor A,Cyclin-dependent kinase inhibitor 2A, isoforms 1_2_3,Homo sapiens,Human,MTS1,MTS-1,Multiple tumor suppressor 1,p16-INK4,p16INK4A,p16-INK4 96T
E0794h ELISA kit CDK4I,CDKN2,CDKN2A,Cyclin-dependent kinase 4 inhibitor A,Cyclin-dependent kinase inhibitor 2A, isoforms 1_2_3,Homo sapiens,Human,MTS1,MTS-1,Multiple tumor suppressor 1,p16-INK4,p16INK4A,p16 96T
EIAAB06559 CDI1,CDK2-associated dual-specificity phosphatase,CDKN3,CIP2,Cyclin-dependent kinase inhibitor 3,Cyclin-dependent kinase interactor 1,Cyclin-dependent kinase-interacting protein 2,Homo sapiens,Human,K
U1943h CLIA kit CDKN2C,CDKN6,Cyclin-dependent kinase 4 inhibitor C,Cyclin-dependent kinase 6 inhibitor,Homo sapiens,Human,p18-INK4c,p18-INK6 96T
U1943h CLIA CDKN2C,CDKN6,Cyclin-dependent kinase 4 inhibitor C,Cyclin-dependent kinase 6 inhibitor,Homo sapiens,Human,p18-INK4c,p18-INK6 96T
E1943h ELISA CDKN2C,CDKN6,Cyclin-dependent kinase 4 inhibitor C,Cyclin-dependent kinase 6 inhibitor,Homo sapiens,Human,p18-INK4c,p18-INK6 96T
E1943h ELISA kit CDKN2C,CDKN6,Cyclin-dependent kinase 4 inhibitor C,Cyclin-dependent kinase 6 inhibitor,Homo sapiens,Human,p18-INK4c,p18-INK6 96T
E1943m ELISA kit Cdkn2c,Cyclin-dependent kinase 4 inhibitor C,Cyclin-dependent kinase 6 inhibitor,Mouse,Mus musculus,p18-INK4c,p18-INK6 96T
E1943m ELISA Cdkn2c,Cyclin-dependent kinase 4 inhibitor C,Cyclin-dependent kinase 6 inhibitor,Mouse,Mus musculus,p18-INK4c,p18-INK6 96T
EIAAB06568 CDKN1C,Cyclin-dependent kinase inhibitor 1C,Cyclin-dependent kinase inhibitor p57,Homo sapiens,Human,KIP2,p57Kip2
U1943m CLIA Cdkn2c,Cyclin-dependent kinase 4 inhibitor C,Cyclin-dependent kinase 6 inhibitor,Mouse,Mus musculus,p18-INK4c,p18-INK6 96T
U1943m CLIA kit Cdkn2c,Cyclin-dependent kinase 4 inhibitor C,Cyclin-dependent kinase 6 inhibitor,Mouse,Mus musculus,p18-INK4c,p18-INK6 96T
EIAAB06565 CDKN1B,Cyclin-dependent kinase inhibitor 1B,Cyclin-dependent kinase inhibitor p27,Homo sapiens,Human,KIP1,p27Kip1
EIAAB06567 Cdkn1c,Cyclin-dependent kinase inhibitor 1C,Cyclin-dependent kinase inhibitor p57,Kip2,Mouse,Mus musculus,p57Kip2
EIAAB06566 Cdkn1b,Cyclin-dependent kinase inhibitor 1B,Cyclin-dependent kinase inhibitor p27,Mouse,Mus musculus,p27Kip1
15-288-22054F Cyclin-dependent kinase 6 inhibitor - p18-INK6; Cyclin-dependent kinase 4 inhibitor C; p18-INK4c Polyclonal 0.05 mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur